Overview
Description
Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company's primary aim is to discover and commercialize novel therapeutics targeting Alzheimer's disease and other neurological disorders. Athira Pharma's lead product candidate is designed to help repair neuronal damage, potentially offering a regenerative approach to these debilitating conditions. The company employs cutting-edge research in protein therapeutics and uses proprietary small molecule therapeutics to improve cognitive function by targeting mechanisms that facilitate neural health and maintenance.
Based in the biopharmaceutical innovation hub of the United States, Athira Pharma plays a significant role in the biotech sector, particularly in the neurology and Alzheimer's treatment market. It operates within a crucial segment of the healthcare industry, addressing some of the most challenging and urgent unmet medical needs. The company's initiatives, driven by scientific research and development, underline its commitment to transforming the treatment landscape for neurodegenerative diseases, contributing to the broader goals of the healthcare and life sciences industries.
About
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Employees
26
Address
18706 North Creek Parkway
Suite 104
Bothell, 98011, WA
United States
Suite 104
Bothell, 98011, WA
United States
Phone
425 620 8501
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNCM